# RSV Infection FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/rsv-infection

> 2 upcoming FDA catalysts in RSV Infection: rsvpref (PFE) on Feb to May 2028 (topline data readout); rsvpref (PFE) on February 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 8, 2025 | [Obeldesivir primary completion](https://sec-api.dev/pdufa/obeldesivir) | GILD | RSV Infection | withdrawn | "NCT06585150 (Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585150)) |
| June 23, 2025 | [EDP-938 primary completion](https://sec-api.dev/pdufa/edp-938) | ENTA | RSV Infection | completed | "NCT05568706 (A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Enanta Pharmaceuticals, Inc; Results First Posted 2026-08-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05568706)) |
| August 19, 2026 | [EDP-938 topline data readout](https://sec-api.dev/pdufa/edp-938) | ENTA | RSV Infection | completed | "NCT05568706 (A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Enanta Pharmaceuticals, Inc; Results First Posted 2026-08-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05568706?tab=results)) |
| Feb to May 2028 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | RSV Infection | scheduled | "NCT06866405 (A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06866405)) |
| February 2028 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | RSV Infection | scheduled | "NCT06866405 (A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06866405)) |

## Drugs

- [Obeldesivir](https://sec-api.dev/pdufa/obeldesivir) (GILD)
- [EDP-938](https://sec-api.dev/pdufa/edp-938) (ENTA)
- [Rsvpref](https://sec-api.dev/pdufa/rsvpref) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/rsv-infection.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RSV Infection FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/rsv-infection

```bibtex
@misc{secapidev_indications_rsv_infection_20261116,
  title        = {RSV Infection FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/rsv-infection}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_rsv_infection_20261116","title":"RSV Infection FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/rsv-infection","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
